Pharmacology, Toxicology and Pharmaceutical Science
Multiple Myeloma
100%
Overall Survival
72%
Imatinib
36%
Thalidomide
36%
Rituximab
33%
Myelodysplastic Syndrome
33%
Bortezomib
33%
Dexamethasone
32%
Progression Free Survival
31%
Diffuse Large B Cell Lymphoma
30%
Cyclophosphamide
28%
Disease
27%
Malignant Neoplasm
27%
Busulfan
26%
Venous Thromboembolism
26%
Lenalidomide
25%
Cyclophosphamide Plus Doxorubicin Plus Prednisolone Plus Rituximab Plus Vincristine
21%
Melphalan
20%
Doxorubicin
20%
Survival Rate
19%
Adverse Event
19%
Chronic Myeloid Leukemia
18%
Acute Lymphoblastic Leukemia
16%
Decitabine
16%
Azacitidine
16%
Remission
16%
Febrile Neutropenia
14%
Clinical Feature
14%
Myeloma
14%
Recurrence Free Survival
14%
Thromboembolism
13%
Paroxysmal Nocturnal Hemoglobinuria
13%
Myeloid Leukemia
13%
Antifungal Therapy
13%
Itraconazole
13%
Prednisone
12%
Observational Study
12%
Vincristine
12%
Hematologic Malignancy
10%
Pomalidomide
10%
Promyelocytic Leukemia
10%
NK T Cell Lymphoma
10%
Radotinib
10%
Reactive Oxygen Metabolite
10%
Fludarabine
10%
Leukotriene B4
10%
Thrombocythemia
10%
Disease Course
8%
Acute Myeloid Leukemia
8%
Infection
8%
Medicine and Dentistry
Multiple Myeloma
86%
Overall Survival
77%
Prognostic Factor
53%
Diffuse Large B-Cell Lymphoma
45%
Autologous Stem Cell Transplantation
43%
Progression Free Survival
36%
Acute Myeloid Leukemia
33%
Disease
30%
Venous Thromboembolism
30%
Bortezomib
29%
Myelodysplastic Syndrome
23%
Idiopathic Thrombocytopenic Purpura
23%
Malignant Neoplasm
22%
Multivariate Analysis
20%
Clinical Feature
20%
Imatinib
20%
Doxorubicin
19%
Rituximab
18%
Dexamethasone
18%
Myeloma
17%
NK T Cell Lymphoma
16%
Lactate Dehydrogenase
15%
Survival Rate
14%
International Prognostic Index
14%
Observational Study
14%
Cyclophosphamide
13%
Paroxysmal Nocturnal Hemoglobinuria
13%
Cord Blood
13%
Vincristine
12%
Adverse Event
12%
Thromboembolism
12%
Cytarabine
12%
Neutrophil
12%
Hematopoietic Cell
11%
Stem Cell Therapy
11%
Chronic Myelogenous Leukemia
11%
Prednisone
11%
Hazard Ratio
11%
Recurrence Free Survival
10%
Somatic Mutation
10%
Acute Lymphoblastic Leukemia
10%
Predictive Factor
10%
Thrombosis
10%
Myeloproliferative Neoplasm
10%
T-Cell Lymphoma
9%
Retrospective Study
9%
Platelet
9%
Febrile Neutropenia
8%
Hematopoietic Stem Cell Transplantation
8%
Melphalan
8%
Biochemistry, Genetics and Molecular Biology
Single-Nucleotide Polymorphism
67%
Myeloid
64%
Overall Survival
55%
Cytogenetics
51%
Karyotyping
44%
Metaphase
35%
Single Nucleotide Polymorphism
27%
Fluorescence in Situ Hybridization
23%
Genotyping
20%
Decitabine
20%
Core Binding Factor
20%
Karyotype
19%
Loss of Heterozygosity
18%
Azacitidine
16%
Dexamethasone
15%
Chromosomal Abnormalities
13%
Event Free Survival
13%
Imatinib
13%
B Cell
12%
Progression Free Survival
12%
Platelet Count
11%
Interphase
11%
Autologous Stem Cell Transplantation
10%
Doxorubicin
9%
High Risk Population
9%
Somatic Mutation
8%
Lactate Dehydrogenase
8%
RUNX1T1
8%
RUNX1
8%
Polymorphonuclear Cell
8%
Chromosome 20q
8%
Clonal Evolution
7%
CD34
7%
Allogeneic Hematopoietic Stem Cell Transplantation
7%
Chromosome 7
7%
Chromosome 5
7%
Rituximab
7%
Hematopoietic Cell
6%
CD44
6%
Exon
6%
ERCC1
6%
Precursor
6%
Human Leukocyte Antigen
6%
Chromosome 13
6%
Conditioning
6%
Monosomy
6%
Philadelphia Chromosome
6%
Busulfan
6%
Ring Chromosome
6%
Immunoglobulin D
6%
